Precision Optics Reports First Quarter Fiscal 2027 Financial Results
PRECISION OPTICS CORPORATION, INC. (POCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRECISION OPTICS CORPORATION 550 King Street, Bldg. A, Suite 100 Littleton, MA 01460 978 / 630-1800 NEWS RELEASE POC26-XXXX FOR IMMEDIATE RELEASE Monday, November 16, 2026 Precision Optics Reports First Quarter Fiscal 2027 Financial Results Conference Call Scheduled
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The quarter showed revenue growth and a sharp gross margin improvement, plus multiple follow-on orders, while fiscal 2027 outlook was maintained with Adjusted EBITDA still expected to be negative.
Market read
Traders can reassess near-term order momentum and profitability trajectory based on the newly reported quarter and maintained FY2027 revenue and Adjusted EBITDA ranges.
What to watch
Adjusted EBITDA remains negative and guidance keeps Adjusted EBITDA in a loss range, so upside may be capped unless orders convert to sustained profitability.
Background
Precision Optics furnished its Q1 FY2027 results via SEC Form 8-K Item 2.02 and included a company earnings release (Exhibit 99.1).
Ticker impact
Precision Optics reported Q1 FY2027 revenue up 22% to $8.2M, gross margin up to 22.5%, and narrowed net loss to $0.04/share.
Likely upward bias as traders price in margin improvement and earlier-than-expected follow-on orders, tempered by lower cash.
The filing provides fresh quarterly results, margin expansion, and specific post-quarter follow-on orders, which are actionable for positioning ahead of subsequent quarters.
Market effects
Signals demand momentum in satellite optical communications and single-use medical device optics, potentially supportive for small-cap specialty optics peers.
Limited direct regional read-through beyond US small-cap medtech and defense supply chains.
Primarily US-focused; satellite communications demand is globally relevant but the disclosure is company-specific.
Counterpoint
Cash and cash equivalents fell to $9.0M from $9.8M, so margin improvement may not translate into near-term balance-sheet strength.
Key entities
- issuerPrecision Optics Corporation
Nasdaq-listed designer and manufacturer of advanced optical instruments for medical and defense/aerospace and satellite communications.
- business_lineSatellite optical communications program
Generated $2.3M in Q1 revenue and received a $2.0M follow-on production order after quarter-end.
- business_lineSingle-use cystoscope program
Generated $1.8M in production revenue during Q1 FY2027.
- business_lineSingle-use ophthalmic program
Delivered $581,000 in Q1 revenue as shipments increased under a $3.5M follow-on order.


